Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.65 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.65 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943704 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL610237 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL30943705 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31061492 | 0.96 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3535232 | 0.89 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3538224 | 0.88 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3538463 | 0.85 | PRKDC (0.78) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31060675 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537126 | 0.85 | PRKDC (0.78) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537842 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694939-A1 | PSMA-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2026-02-18 | — | — | EP | claimed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250236892-A1 | Inhibition of NHEJ, MMEJ, and 53BP1 Promotes High Levels of HDR | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2025-07-24 | — | — | US | claimed |
| US-20250177581-A1 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | FUSION PHARMACEUTICALS INC (CA) | 2025-06-05 | — | — | US | claimed |
| US-20250154531-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | LIFE TECHNOLOGIES CORP (US) | 2025-05-15 | — | — | US | claimed |
| US-20250122538-A1 | Compounds for Increasing Genome Editing Efficiency | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2025-04-17 | — | — | US | claimed |
| WO-2025056970-A1 | MAMMALIAN CELL CULTURE ADDITIVES | VIROCELL BIOLOGICS LTD (GB) | 2025-03-20 | — | — | WO | claimed |
| WO-2025049985-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING AN INHIBITOR OF PRM T5 | PURDUE RESEARCH FOUNDATION (US) | 2025-03-06 | — | — | WO | claimed |
| US-20230070047-A1 | METHOD TO ENHANCE GENE EDITING | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-03-09 | — | — | US | claimed |
| EP-4121564-A1 | BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY | Immunomedics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| CN-115398010-A | Biomarkers for Goxatuzumab therapy | 免疫医疗公司 | 2022-11-25 | — | — | CN | claimed |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | THE BROAD INSTITUTE, INC. (US) | 2022-10-18 | — | — | US | claimed |
| EP-4051787-A1 | GIN RECOMBINASE VARIANTS | Sangamo Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220243228-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | FACTOR BIOSCIENCE INC (US) | 2022-08-04 | — | — | US | claimed |
| US-20220211783-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | TRINITY CAPITAL INC., AS AGENT | 2022-07-07 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| EP-3955943-A1 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | Candel Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| CN-108686221-B | Synergistic antitumor drug | 广州威溶特医药科技有限公司 | 2022-02-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177581-A1 | NTSR1-TARGETED RADIOPHARMACEUTICALS AND DNA DAMAGE RESPONSE INHIBITOR COMBINATION THERAPY | NTSR1, NTSR2, NPSR1 | PRKDC 2695/4885PIK3CA 4164/4885MTOR 2248/4885 |
| US-11471462-B2 | Compositions and methods for detecting and treating diabetes | SLC2A2, SLC2A1, SLC5A2 | PRKDC 4507/4885PIK3CA 3008/4885MTOR 3599/4885 |
| US-20220243228-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | EIF2AK2, NSUN3, TARBP1 | PRKDC 1673/4885PIK3CA 4466/4885MTOR 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.